225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks
Abstract
Ac-based PSMA-targeted therapy has emerged as promising agent for the treatment of metastatic castration-resistant prostate cancer. Posttherapy image is used for tracer localization and dosimetry. Prior 2 photopeaks of 440 and 218 KeV were reported for posttherapy imaging. Our study of gamma ray spectrum, phantom, and clinical images show that imaging with 3 major photopeaks of 78, 218, and 440 KeV gives better quality images, high count statistics, and higher number of lesion delineations. It is therefore suggested that posttherapy imaging may be carried out using 3 major abundant photopeaks.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The literature showing the feasibility of using the three photopeaks is limited to only a few clinical case reports.
“the literature showing the feasibility of using the three photopeaks is limited to only few clinical case reports (108, 109).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [108]
Cites
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636 · see citing works
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429 · see citing works
Heck, M. M., Retz, M. M., D’Alessandria, C., Rauscher, I., Scheidhauer, K., Maurer, T., Storz, E., Janssen, F., Schottelius, M., Wester, H., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.02.2969 · Cited by 187 · see citing works
Hong, S., Hobbs, R. F., Vajravelu, R. K., Huso, D. L., Esaias, C. E., Apostolidis, C., Morgenstern, A., & Sgouros, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1828 · Cited by 158 · see citing works
The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides
Ackerman, N. L., & Graves, E. E. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/3/771 · Cited by 46 · see citing works
van der Doelen, M. J., Mehra, N., Smits, M., van Oort, I. M., Janssen, M. J. R., Haberkorn, U., Kratochwil, C., & Gerritsen, W. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.344 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Radionuclides for Targeted Therapy: Physical Properties
Stokke, C., Kvassheim, M., & Blakkisrud, J. (2022) · Molecules · doi:10.3390/molecules27175429 · Cited by 105 · see citing works
Actinium-225 targeted alpha particle therapy for prostate cancer
Bidkar, A. P., Zerefa, L., Yadav, S., VanBrocklin, H. F., & Flavell, R. R. (2024) · Theranostics · doi:10.7150/thno.96403 · Cited by 90 · see citing works
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares, R. M., & Abergel, R. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1020188 · Cited by 64 · see citing works
Global experience with PSMA-based alpha therapy in prostate cancer
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Morgenstern, A., & Lawal, I. O. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05434-9 · Cited by 57 · see citing works
Delker, A., Schleske, M., Liubchenko, G., Berg, I., Zacherl, M. J., Brendel, M., Gildehaus, F. J., Rumiantcev, M., Resch, S., Hürkamp, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06092-1 · Cited by 53 · see citing works
Ahmadzadehfar, H., Rahbar, K., Essler, M., & Biersack, H. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.003 · Cited by 53 · see citing works
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
Gosewisch, A., Schleske, M., Gildehaus, F. J., Berg, I., Kaiser, L., Brosch-Lenz, J., Bartenstein, P., Todica, A. S., Ilhan, H., & Böning, G. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05024-1 · Cited by 46 · see citing works
Benabdallah, N., Scheve, W., Dunn, N., Silvestros, D., Schelker, P., Abou, D. S., Jammalamadaka, U. M., Laforest, R. A., Li, Z., Liu, J., et al. (2021) · Theranostics · doi:10.7150/thno.63860 · Cited by 46 · see citing works
Liubchenko, G., Böning, G., Zacherl, M. J., Rumiantcev, M., Unterrainer, L. M., Gildehaus, F. J., Brendel, M., Resch, S., Bartenstein, P., Ziegler, S. I., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06681-2 · Cited by 41 · see citing works
Why bother with alpha particles?
King, A. P., Lin, F. I., & Escorcia, F. E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05431-y · Cited by 40 · see citing works
Quantitative SPECT/CT imaging of lead-212: a phantom study
Kvassheim, M., Revheim, M.-E. R., & Stokke, C. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00481-z · Cited by 37 · see citing works
Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas
Tulik, M., Kuliński, R., Tabor, Z., Brzozowska, B., Łaba, P., Bruchertseifer, F., Morgenstern, A., Królicki, L., & Kunikowska, J. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00635-1 · Cited by 30 · see citing works
Vatsa, R., Sood, A., Vadi, S. K., Das, C. K., Kaur, K., Parmar, M., & Mittal, B. R. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003031 · Cited by 23 · see citing works
Ac-EAZY! Towards GMP-Compliant Module Syntheses of 225Ac-Labeled Peptides for Clinical Application
Pretze, M., Kunkel, F., Runge, R., Freudenberg, R., Braune, A., Hartmann, H., Schwarz, U., Brogsitter, C., & Kotzerke, J. (2021) · Pharmaceuticals · doi:10.3390/ph14070652 · Cited by 18 · see citing works
Rodríguez, J. C., Huh, Y., Gullberg, G. T., & Seo, Y. (2022) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2022.3166116 · Cited by 19 · see citing works
Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment
Roncali, L., Hindré, F., Samarut, É., Lacœuille, F., Rousseau, A., D, J.-M. L. M., Garcion, E., & Chérel, M. (2025) · Theranostics · doi:10.7150/thno.106081 · Cited by 16 · see citing works
Nanoliposome-based drug delivery systems for the treatment of diabetes mellitus: a review
Umar, M., Sherazi, T. A., Talha, M., Ramadan, M. F., Ahmed, A. E., Taha, R., & Naqvi, S. A. R. (2025) · RSC Advances · doi:10.1039/d5ra07152f · Cited by 10 · see citing works
Self-citationIsrael, J. S., Marcelin, L.-M., Thomas, C., Szczyrbová, E., Fuessel, S., Puhr, M., Linxweiler, J., Yalala, S., Zwart, W. T., Baniahmad, A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03125-5 · Cited by 10 · see citing works
EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters
Gabiña, P. M., Gleisner, K. S., Chouin, N., Tran‐Gia, J., Koole, M., Cremonesi, M., Denis-Bacelar, A. M., Cassano, B., Verburg, F. A., Brosch-Lenz, J., et al. (2026) · EANM Innovation · doi:10.1016/j.eanmi.2025.100018 · Cited by 5 · see citing works
Theranostics Nuclear Medicine in Prostate Cancer
de Lima, H. D. C. L., Etchebehere, M., Bogoni, M., Torricelli, C., Lima, E. N., Deflon, V. M., Lima, M., & Etchebehere, E. (2024) · Pharmaceuticals · doi:10.3390/ph17111483 · Cited by 4 · see citing works
Pretze, M., Wendrich, J., Hartmann, H., Freudenberg, R., Bundschuh, R. A., Kotzerke, J., & Michler, E. (2024) · Pharmaceuticals · doi:10.3390/ph18010026 · Cited by 2 · see citing works
Liubchenko, G., Böning, G., Rumiantcev, M., Zounek, A. J., Zacherl, M. J., Sheikh, G. T., Resch, S., Werner, R. A., Ziegler, S. I., & Delker, A. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00800-0 · Cited by 2 · see citing works
Qualitative and quantitative imaging of alpha‐emitting radiopharmaceuticals
Wang, L., Lou, J., Cao, X., Jia, L., Xue, S., Liu, X., Zhang, L., & Li, X. (2024) · iRadiology · doi:10.1002/ird3.89 · Cited by 2 · see citing works
Bentonite clay in aflatoxin mitigation: advances, efficiency and perspectives
Naqvi, S. A. R., Khosa, M. K., Zahoor, A. F., Ahmad, M., Abdullah, A. B. M., Janjua, M. R. S. A., Abidi, S. A., Khalil, F. M. A., Ramadan, M. F., & Rocha, J. M. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04584-w · Cited by 1 · see citing works
Self-citationLing, S. W., Konijnenberg, M., Segbers, M., Hooijman, E. L., Koolen, S. L. W., de Blois, E., de Jong, L. C., van Puffelen, A. J., de Lussanet, Q. G., Bruchertseifer, F., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271880 · Cited by 2 · see citing works
Naqvi, S. A. R., Naz, S., Irfan, M., Zahoor, A. F., Randhawa, A. H., Rocha, J. M., & Ramadan, M. F. (2026) · South African Journal of Botany · doi:10.1016/j.sajb.2026.04.030 · Cited by 1 · see citing works
Self-citationSomoto, T., Utsumi, T., Ikeda, R., Sugimoto, T., Ishitsuka, N., Kadono, Y., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., et al. (2026) · Cancers · doi:10.3390/cancers18121966 · Cited by 2 · see citing works
Okşaş, H., & Ekinci, M. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112023
Azhari, H. F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1581598
Additional file 1 of Quantitative SPECT/CT imaging of lead-212: a phantom study
Kvassheim, M., Revheim, M.-E. R., & Stokke, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438363
Maurer, K., Unger, D., Béhé, M. P., Knecht, A., von Schoeler, K., Hengstler, D., Vitova, T., Benešová, M., Fleischmann, A., Gastaldo, L., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01377-0
Batool, A., Jabar, T., Fatima, S. M., Waji-Ul-Hassan, S. M., Rubab, N., Ahmad, H. K. N., Ramadan, M. F., Aldawood, N., Alkahtani, T. O., Alshihri, A. A., et al. (2026) · RSC Advances · doi:10.1039/d6ra08252a
Self-citationRadioimmunotherapy: Mechanisms, Strategies, and Advances in Therapeutic Enhancement
Naqvi, D. S. A. R., Fatima, S. M., Waji-Ul-Hassan, S. M., Gursal, S. A., Fatima, S., Imran, M. B., Wasim, M., Ramadan, M. F., & Lodhi, N. A. (2026) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785261486288
Jokar, N., Pashazadeh, A., Juweid, M. E., Najdian, A., Jafari, E., Mottaghy, F. M., Assadi, M., & Sathekge, M. M. (2026) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2026.09.002
- Authors
- Usmani, S., Rasheed, R., Al kandari, F., Marafi, F., & Naqvi, S. A. R.
- Affiliations
- Kuwait Cancer Control Center (KW)
- Government College University, Faisalabad (PK)
- Kuwait Cancer Control Centre (KCCC), Kuwait City, Kuwait;
- Jaber Al-Ahmad Centre for Nuclear Medicine and Molecular Imaging, Kuwait City, Kuwait.
- Corresponding author
- Usmani, Sharjeel
- Rasheed, Rashid
- Venue
- Clinical Nuclear Medicine
- Published
- 2019-05
- Volume
- 44
- Issue
- 5
- Pages
- 401-403
- ISSN
- 0363-9762 (ISSN-L)
- 1536-0229
- OpenAlex
- W2926561902
- Cited by
- 35
- References
- 7
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 1
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- actinium-225, prostate-specific membrane antigen, PSMA-targeted therapy, gamma-ray spectra, photopeak, metastatic castration-resistant prostate cancer, dosimetry, phantoms
- MeSH terms
- Actinium, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Radiometry, Reference Standards, Prostate-Specific Antigen, Radiopharmaceuticals, Positron-Emission Tomography, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
